SPARTALIZUMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 13:10:56 GMT 2023` Edited by `admin` on `Sat Dec 16 13:10:56 GMT 2023`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG4
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	QOG25L6Z8Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SPARTALIZUMAB

Official Name

English

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS PROGRAMMED CELL DEATH PROTEIN 1 (PROTEIN PD-1, CD-279 ANTIGEN))HUMANIZED MONOCLONAL ANTIBODY.GAMMA.4 HEAVY CHAIN (1-443) (HUMANIZED VH (HOMO SAPIENS IGHV1-69-2*01 (75%) (IGHD)-IGHJ6*01) (8.8.10) (1-117)-HOMO SA

Systematic Name

English

PDR-001

Code

English

IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1)(HUMAN-MUS MUSCULUS MONOCLONAL CLONE NVS240118 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CLONE NVS240118 .KAPPA.-CHAIN, DIMER

Systematic Name

English

NVP-LZV184

Code

English

SPARTALIZUMAB [JAN]

Common Name

English

SPARTALIZUMAB [USAN]

Common Name

English

spartalizumab [INN]

Common Name

English

Spartalizumab [WHO-DD]

Common Name

English

PDR001

Code

English

ANTI-PD1 MONOCLONAL ANTIBODY PDR001

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C129822

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

FDA ORPHAN DRUG

653418

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

NCI_THESAURUS

C128037

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

FDA ORPHAN DRUG

819321

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

FDA ORPHAN DRUG

576417

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

Code System Code Type Description

CAS

1935694-88-4

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

PRIMARY

INN

10624

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

PRIMARY

NCI_THESAURUS

C121625

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

PRIMARY

DRUG BANK

DB14892

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

PRIMARY

USAN

GH-36

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

PRIMARY

FDA UNII

QOG25L6Z8Z

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

PRIMARY

WIKIPEDIA

Spartalizumab

Created by admin on Sat Dec 16 13:10:56 GMT 2023 , Edited by admin on Sat Dec 16 13:10:56 GMT 2023

PRIMARY

From	To
1_22	1_96
1_131	3_220
1_144	1_200
1_223	2_223
1_226	2_226
1_258	1_318
1_364	1_422
2_22	2_96
2_131	4_220
2_144	2_200
2_258	2_318
2_364	2_422
3_23	3_94
3_140	3_200
4_23	4_94
4_140	4_200

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_294
N	2_294

Related Record Type Details


					938DNF64FO

PROGRAMMED CELL DEATH PROTEIN 1

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					QOG25L6Z8Z

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL